Artivion Finalizes $135M Endospan Acquisition, Securing FDA-Approved Aortic Arch System
AORT sits 23% above its 52-week low of $19.16.
Summary
Artivion completed its acquisition of Endospan for $135 million upfront cash, plus up to $200 million in contingent payments, integrating the recently FDA-approved Nexus® Aortic Arch System into its portfolio.
Key Events · M&A and Partnerships · AORT
-
Acquisition Completed
Artivion finalized the acquisition of Endospan Ltd. for an upfront net cash purchase price of $135 million. This follows the announcement of the acquisition on May 7, 2026.
-
Strategic Product Integration
The acquisition integrates the FDA-approved NEXUS® Aortic Arch System, completing Artivion's aortic arch portfolio and adding a robust pipeline of next-generation technologies. Artivion has been the exclusive distributor of the NEXUS System across EMEA since 2019.
-
Contingent Consideration
The deal includes potential additional consideration of up to $200 million based on the future commercial performance of Endospan's Nexus™ product, which would be determined and payable approximately two years post-closing.
-
Funding Source
The upfront cash payment was funded by Artivion's previously drawn $150 million delayed draw term loan.
Analysis · AORT · Industrial Applications And Services
Artivion has completed the acquisition of Endospan, a strategic move that significantly expands its aortic arch portfolio. The deal, valued at $135 million upfront cash with up to $200 million in contingent payments, follows the recent U.S. FDA approval of Endospan's Nexus® Aortic Arch System in April 2026. This acquisition integrates a key product and pipeline, positioning Artivion as a leader in aortic arch solutions.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AORT was trading at $23.54 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $19.16 to $48.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.